{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,19]],"date-time":"2026-07-19T05:14:40Z","timestamp":1784438080029,"version":"3.55.0"},"reference-count":78,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,3,13]],"date-time":"2026-03-13T00:00:00Z","timestamp":1773360000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T00:00:00Z","timestamp":1777420800000},"content-version":"vor","delay-in-days":47,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["npj Vaccines"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>The 24th International Pathogenic Neisseria Conference (IPNC) marked a shift toward a balanced forum addressing both meningococcal and gonococcal disease. This drove discussion on how multivalent meningococcal vaccines are enabling the WHO roadmap to defeat meningitis by 2030, while highlighting growing evidence that effective gonococcal vaccines are achievable. Major challenges remain, including antimicrobial resistance, limited genomic surveillance and incomplete understanding of pathogenesis and immune evasion. These reflections shaped this perspective piece.<\/jats:p>","DOI":"10.1038\/s41541-026-01417-9","type":"journal-article","created":{"date-parts":[[2026,3,13]],"date-time":"2026-03-13T09:46:18Z","timestamp":1773395178000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Perspective on the pathogenic Neisseria: milestones, challenges, and future directions"],"prefix":"10.1038","volume":"11","author":[{"given":"Joseph A.","family":"Duncan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ann E.","family":"Jerse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federico","family":"Martin\u00f3n-Torres","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariagrazia","family":"Pizza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rino","family":"Rappuoli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David S.","family":"Stephens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christoph M.","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,13]]},"reference":[{"key":"1417_CR1","doi-asserted-by":"publisher","first-page":"2196","DOI":"10.1016\/S0140-6736(07)61016-2","volume":"369","author":"DS Stephens","year":"2007","unstructured":"Stephens, D. S., Greenwood, B. & Brandtzaeg, P. Epidemic meningitis, meningococcaemia, and Neisseria meningitidis. Lancet 369, 2196\u20132210 (2007).","journal-title":"Lancet"},{"key":"1417_CR2","doi-asserted-by":"publisher","first-page":"1949","DOI":"10.1128\/JCM.00301-16","volume":"54","author":"MC Maiden","year":"2016","unstructured":"Maiden, M. C. & Harrison, O. B. Population and Functional Genomics of Neisseria Revealed with Gene-by-Gene Approaches. J. Clin. Microbiol 54, 1949\u20131955 (2016).","journal-title":"J. Clin. Microbiol"},{"key":"1417_CR3","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1038\/s41579-019-0282-6","volume":"18","author":"DA Caugant","year":"2020","unstructured":"Caugant, D. A. & Brynildsrud, O. B. Neisseria meningitidis: using genomics to understand diversity, evolution and pathogenesis. Nat. Rev. Microbiol. 18, 84\u201396 (2020).","journal-title":"Nat. Rev. Microbiol."},{"key":"1417_CR4","doi-asserted-by":"publisher","first-page":"973","DOI":"10.15585\/mmwr.mm7343a3","volume":"73","author":"M Robinson","year":"2024","unstructured":"Robinson, M. et al. Statewide Outbreak of Neisseria meningitidis Serogroup Y, Sequence Type 1466 - Virginia, 2022-2024. MMWR Morb. Mortal. Wkly Rep. 73, 973\u2013977 (2024).","journal-title":"MMWR Morb. Mortal. Wkly Rep."},{"key":"1417_CR5","doi-asserted-by":"publisher","first-page":"e0021524","DOI":"10.1128\/cmr.00215-24","volume":"38","author":"E Rodriguez","year":"2025","unstructured":"Rodriguez, E. et al. Progression of antibiotic resistance in Neisseria meningitidis. Clin. Microbiol Rev. 38, e0021524 (2025).","journal-title":"Clin. Microbiol Rev."},{"key":"1417_CR6","doi-asserted-by":"publisher","DOI":"10.1186\/s12864-018-4560-x","volume":"19","author":"AC Retchless","year":"2018","unstructured":"Retchless, A. C. et al. Expansion of a urethritis-associated Neisseria meningitidis clade in the United States with concurrent acquisition of N. gonorrhoeae alleles. BMC Genomics 19, 176 (2018).","journal-title":"BMC Genomics"},{"key":"1417_CR7","doi-asserted-by":"publisher","first-page":"1816","DOI":"10.1093\/infdis\/jiaa002","volume":"222","author":"OB Harrison","year":"2020","unstructured":"Harrison, O. B. et al. Neisseria gonorrhoeae Population Genomics: Use of the Gonococcal Core Genome to Improve Surveillance of Antimicrobial Resistance. J. Infect. Dis. 222, 1816\u20131825 (2020).","journal-title":"J. Infect. Dis."},{"key":"1417_CR8","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1097\/QCO.0000000000000997","volume":"37","author":"EPF Chow","year":"2024","unstructured":"Chow, E. P. F., Fairley, C. K. & Kong, F. Y. S. STI pathogens in the oropharynx: update on screening and treatment. Curr. Opin. Infect. Dis. 37, 35\u201345 (2024).","journal-title":"Curr. Opin. Infect. Dis."},{"key":"1417_CR9","doi-asserted-by":"publisher","first-page":"e0332073","DOI":"10.1371\/journal.pone.0332073","volume":"20","author":"C Carrillo Infante","year":"2025","unstructured":"Carrillo Infante, C. & Mujeebuddin, A. Eculizumab and ravulizumab clinical trial and real-world pharmacovigilance of meningococcal infections across indications. PLoS One 20, e0332073 (2025).","journal-title":"PLoS One"},{"key":"1417_CR10","doi-asserted-by":"publisher","first-page":"596","DOI":"10.1093\/cid\/ciy958","volume":"69","author":"PE Crew","year":"2019","unstructured":"Crew, P. E. et al. Disseminated Gonococcal Infections in Patients Receiving Eculizumab: A Case Series. Clin. Infect. Dis. 69, 596\u2013600 (2019).","journal-title":"Clin. Infect. Dis."},{"key":"1417_CR11","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1093\/cid\/cis892","volume":"56","author":"PA Kristiansen","year":"2013","unstructured":"Kristiansen, P. A. et al. Impact of the serogroup A meningococcal conjugate vaccine, MenAfriVac, on carriage and herd immunity. Clin. Infect. Dis. 56, 354\u2013363 (2013).","journal-title":"Clin. Infect. Dis."},{"key":"1417_CR12","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1136\/bmj.326.7385.365","volume":"326","author":"ME Ramsay","year":"2003","unstructured":"Ramsay, M. E., Andrews, N. J., Trotter, C. L., Kaczmarski, E. B. & Miller, E. Herd immunity from meningococcal serogroup C conjugate vaccination in England: database analysis. BMJ 326, 365\u2013366 (2003).","journal-title":"BMJ"},{"key":"1417_CR13","doi-asserted-by":"publisher","first-page":"4097","DOI":"10.1016\/j.vaccine.2005.03.045","volume":"23","author":"A Larrauri","year":"2005","unstructured":"Larrauri, A., Cano, R., Garcia, M. & Mateo, S. Impact and effectiveness of meningococcal C conjugate vaccine following its introduction in Spain. Vaccine 23, 4097\u20134100 (2005).","journal-title":"Vaccine"},{"key":"1417_CR14","doi-asserted-by":"publisher","first-page":"1649 e1641","DOI":"10.1016\/j.cmi.2022.07.004","volume":"28","author":"JP Carr","year":"2022","unstructured":"Carr, J. P. et al. Impact of meningococcal ACWY conjugate vaccines on pharyngeal carriage in adolescents: evidence for herd protection from the UK MenACWY programme. Clin. Microbiol Infect. 28, 1649 e1641\u20131649 e1648 (2022).","journal-title":"Clin. Microbiol Infect."},{"key":"1417_CR15","doi-asserted-by":"publisher","first-page":"e609","DOI":"10.1093\/cid\/ciaa1733","volume":"73","author":"M McMillan","year":"2021","unstructured":"McMillan, M. et al. Effectiveness of Meningococcal Vaccines at Reducing Invasive Meningococcal Disease and Pharyngeal Neisseria meningitidis Carriage: A Systematic Review and Meta-analysis. Clin. Infect. Dis. 73, e609\u2013e619 (2021).","journal-title":"Clin. Infect. Dis."},{"key":"1417_CR16","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.jinf.2021.04.031","volume":"83","author":"F Martinon-Torres","year":"2021","unstructured":"Martinon-Torres, F. et al. Recent advances in meningococcal B disease prevention: real-world evidence from 4CMenB vaccination. J. Infect. 83, 17\u201326 (2021).","journal-title":"J. Infect."},{"key":"1417_CR17","doi-asserted-by":"publisher","first-page":"2357924","DOI":"10.1080\/21645515.2024.2357924","volume":"20","author":"V Abitbol","year":"2024","unstructured":"Abitbol, V. et al. 4CMenB journey to the 10-year anniversary and beyond. Hum. Vaccin Immunother. 20, 2357924 (2024).","journal-title":"Hum. Vaccin Immunother."},{"key":"1417_CR18","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1016\/S1473-3099(21)00754-4","volume":"22","author":"B Wang","year":"2022","unstructured":"Wang, B. et al. Effectiveness and impact of the 4CMenB vaccine against invasive serogroup B meningococcal disease and gonorrhoea in an infant, child, and adolescent programme: an observational cohort and case-control study. Lancet Infect. Dis. 22, 1011\u20131020 (2022).","journal-title":"Lancet Infect. Dis."},{"key":"1417_CR19","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1111\/jcpt.13083","volume":"45","author":"C Burman","year":"2020","unstructured":"Burman, C., Alderfer, J. & Snow, V. T. A review of the immunogenicity, safety and current recommendations for the meningococcal serogroup B vaccine, MenB-FHbp. J. Clin. Pharm. Ther. 45, 270\u2013281 (2020).","journal-title":"J. Clin. Pharm. Ther."},{"key":"1417_CR20","doi-asserted-by":"publisher","first-page":"ofae726","DOI":"10.1093\/ofid\/ofae726","volume":"12","author":"B Wang","year":"2025","unstructured":"Wang, B. et al. Long-term 4CMenB Vaccine Effectiveness Against Gonococcal Infection at Four Years Post-Program Implementation: Observational Case-Control Study. Open Forum Infect. Dis. 12, ofae726 (2025).","journal-title":"Open Forum Infect. Dis."},{"key":"1417_CR21","doi-asserted-by":"publisher","first-page":"1168","DOI":"10.1016\/S1473-3099(25)00468-2","volume":"25","author":"SN Ladhani","year":"2025","unstructured":"Ladhani, S. N., Ramsay, M. E. & Fifer, H. What can be learnt from the world\u2019s first national vaccination programme against gonorrhoea. Lancet Infect. Dis. 25, 1168\u20131170 (2025).","journal-title":"Lancet Infect. Dis."},{"key":"1417_CR22","doi-asserted-by":"publisher","first-page":"e625","DOI":"10.1016\/S1473-3099(25)00543-2","volume":"25","author":"F Martinon-Torres","year":"2025","unstructured":"Martinon-Torres, F. & Duran-Parrondo, C. Galicia\u2019s gonorrhoea vaccination programme. Lancet Infect. Dis. 25, e625 (2025).","journal-title":"Lancet Infect. Dis."},{"key":"1417_CR23","unstructured":"Centers for Disease Control and Prevention. Meningococcal vaccine recommendations, https:\/\/www.cdc.gov\/meningococcal\/hcp\/vaccine-recommendations\/index.html (2025)."},{"key":"1417_CR24","doi-asserted-by":"publisher","first-page":"2559506","DOI":"10.1080\/21645515.2025.2559506","volume":"21","author":"MR Alderson","year":"2025","unstructured":"Alderson, M. R. et al. Development of MenFive(R), an affordable pentavalent meningococcal conjugate vaccine (ACYWX) for Africa and beyond. Hum. Vaccin Immunother. 21, 2559506 (2025).","journal-title":"Hum. Vaccin Immunother."},{"key":"1417_CR25","doi-asserted-by":"publisher","first-page":"eade3901","DOI":"10.1126\/scitranslmed.ade3901","volume":"15","author":"C Dold","year":"2023","unstructured":"Dold, C. et al. An adenoviral-vectored vaccine confers seroprotection against capsular group B meningococcal disease. Sci. Transl. Med 15, eade3901 (2023).","journal-title":"Sci. Transl. Med"},{"key":"1417_CR26","doi-asserted-by":"publisher","first-page":"715393","DOI":"10.3389\/fimmu.2021.715393","volume":"12","author":"F Mancini","year":"2021","unstructured":"Mancini, F. et al. GMMA-Based Vaccines: The Known and The Unknown. Front Immunol. 12, 715393 (2021).","journal-title":"Front Immunol."},{"key":"1417_CR27","doi-asserted-by":"publisher","first-page":"e931","DOI":"10.1016\/S2666-5247(22)00283-X","volume":"3","author":"AP Dale","year":"2022","unstructured":"Dale, A. P. et al. Effect of colonisation with Neisseria lactamica on cross-reactive anti-meningococcal B-cell responses: a randomised, controlled, human infection trial. Lancet Microbe 3, e931\u2013e943 (2022).","journal-title":"Lancet Microbe"},{"key":"1417_CR28","doi-asserted-by":"publisher","first-page":"126312","DOI":"10.1016\/j.vaccine.2024.126312","volume":"42","author":"WE Abara","year":"2024","unstructured":"Abara, W. E. et al. Effectiveness of a serogroup B meningococcal vaccine against gonorrhea: A retrospective study. Vaccine 42, 126312 (2024).","journal-title":"Vaccine"},{"key":"1417_CR29","doi-asserted-by":"publisher","first-page":"127180","DOI":"10.1016\/j.vaccine.2025.127180","volume":"56","author":"N Georgiadis","year":"2025","unstructured":"Georgiadis, N. et al. Cross-protection of meningococcal B vaccines against gonorrhea: A systematic review and Meta-analysis. Vaccine 56, 127180 (2025).","journal-title":"Vaccine"},{"key":"1417_CR30","doi-asserted-by":"publisher","first-page":"650","DOI":"10.1093\/infdis\/jiab450","volume":"225","author":"KA Matthias","year":"2022","unstructured":"Matthias, K. A. et al. Meningococcal Detoxified Outer Membrane Vesicle Vaccines Enhance Gonococcal Clearance in a Murine Infection Model. J. Infect. Dis. 225, 650\u2013660 (2022).","journal-title":"J. Infect. Dis."},{"key":"1417_CR31","doi-asserted-by":"publisher","first-page":"1594","DOI":"10.1038\/mi.2017.11","volume":"10","author":"Y Liu","year":"2017","unstructured":"Liu, Y. et al. Experimental vaccine induces Th1-driven immune responses and resistance to Neisseria gonorrhoeae infection in a murine model. Mucosal Immunol. 10, 1594\u20131608 (2017).","journal-title":"Mucosal Immunol."},{"key":"1417_CR32","doi-asserted-by":"publisher","first-page":"e0038822","DOI":"10.1128\/msphere.00388-22","volume":"8","author":"Y Liu","year":"2023","unstructured":"Liu, Y. et al. Microencapsulated IL-12 Drives Genital Tract Immune Responses to Intranasal Gonococcal Outer Membrane Vesicle Vaccine and Induces Resistance to Vaginal Infection with Diverse Strains of Neisseria gonorrhoeae. mSphere 8, e0038822 (2023).","journal-title":"mSphere"},{"key":"1417_CR33","doi-asserted-by":"publisher","first-page":"e1012688","DOI":"10.1371\/journal.ppat.1012688","volume":"20","author":"RA Jones","year":"2024","unstructured":"Jones, R. A. et al. Tackling immunosuppression by Neisseria gonorrhoeae to facilitate vaccine design. PLoS Pathog. 20, e1012688 (2024).","journal-title":"PLoS Pathog."},{"key":"1417_CR34","doi-asserted-by":"publisher","unstructured":"Giuntini, S., Tefera, S. W., Bolanos, A., Ramos Rivera, A. & Moe, G. R. A Combination Native Outer Membrane Vesicle (NOVM) Vaccine to Prevent Meningococcal and Gonococcal Disease. Pathogens 14 https:\/\/doi.org\/10.3390\/pathogens14100979 (2025).","DOI":"10.3390\/pathogens14100979"},{"key":"1417_CR35","doi-asserted-by":"publisher","first-page":"123182","DOI":"10.1016\/j.ijpharm.2023.123182","volume":"642","author":"P Bagwe","year":"2023","unstructured":"Bagwe, P. et al. Gonococcal microparticle vaccine in dissolving microneedles induced immunity and enhanced bacterial clearance in infected mice. Int J. Pharm. 642, 123182 (2023).","journal-title":"Int J. Pharm."},{"key":"1417_CR36","doi-asserted-by":"publisher","DOI":"10.1038\/s41541-024-01054-0","volume":"10","author":"JE Fegan","year":"2025","unstructured":"Fegan, J. E. et al. Rational selection of TbpB variants yields a bivalent vaccine with broad coverage against Neisseria gonorrhoeae. NPJ Vaccines 10, 10 (2025).","journal-title":"NPJ Vaccines"},{"key":"1417_CR37","doi-asserted-by":"publisher","first-page":"8175","DOI":"10.1016\/j.vaccine.2020.10.077","volume":"38","author":"AE Sikora","year":"2020","unstructured":"Sikora, A. E. et al. A novel gonorrhea vaccine composed of MetQ lipoprotein formulated with CpG shortens experimental murine infection. Vaccine 38, 8175\u20138184 (2020).","journal-title":"Vaccine"},{"key":"1417_CR38","doi-asserted-by":"publisher","DOI":"10.1080\/22221751.2023.2249124","volume":"12","author":"S Song","year":"2023","unstructured":"Song, S. et al. Th1-polarized MtrE-based gonococcal vaccines display prophylactic and therapeutic efficacy. Emerg. Microbes Infect. 12, 2249124 (2023).","journal-title":"Emerg. Microbes Infect."},{"key":"1417_CR39","doi-asserted-by":"publisher","first-page":"3835","DOI":"10.1016\/j.vaccine.2022.05.032","volume":"40","author":"CM Chang","year":"2022","unstructured":"Chang, C. M. et al. Application of a Neisseria meningitidis antigen microarray to identify candidate vaccine proteins from a human Phase I clinical trial. Vaccine 40, 3835\u20133842 (2022).","journal-title":"Vaccine"},{"key":"1417_CR40","doi-asserted-by":"publisher","first-page":"852","DOI":"10.1093\/infdis\/jiae153","volume":"230","author":"EL Stover","year":"2024","unstructured":"Stover, E. L. et al. Development and Validation of Multiplex Assays for Mouse and Human IgG and IgA to Neisseria gonorrhoeae Antigens. J. Infect. Dis. 230, 852\u2013856 (2024).","journal-title":"J. Infect. Dis."},{"key":"1417_CR41","doi-asserted-by":"publisher","first-page":"1539795","DOI":"10.3389\/fimmu.2025.1539795","volume":"16","author":"W Zhu","year":"2025","unstructured":"Zhu, W. et al. Protection against N. gonorrhoeae induced by OMV-based meningococcal vaccines are associated with cross-species directed humoral and cellular immune responses. Front Immunol. 16, 1539795 (2025).","journal-title":"Front Immunol."},{"key":"1417_CR42","doi-asserted-by":"publisher","first-page":"e0094024","DOI":"10.1128\/msphere.00940-24","volume":"10","author":"JJ Zeppa","year":"2025","unstructured":"Zeppa, J. J. et al. Meningococcal vaccine 4CMenB elicits a robust cellular immune response that targets but is not consistently protective against Neisseria gonorrhoeae during murine vaginal infection. mSphere 10, e0094024 (2025).","journal-title":"mSphere"},{"key":"1417_CR43","doi-asserted-by":"publisher","first-page":"321","DOI":"10.3389\/fimmu.2019.00321","volume":"10","author":"S Gulati","year":"2019","unstructured":"Gulati, S., Shaughnessy, J., Ram, S. & Rice, P. A. Targeting Lipooligosaccharide (LOS) for a Gonococcal Vaccine. Front Immunol. 10, 321 (2019).","journal-title":"Front Immunol."},{"key":"1417_CR44","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1038\/mi.2012.12","volume":"5","author":"Y Liu","year":"2012","unstructured":"Liu, Y., Islam, E. A., Jarvis, G. A., Gray-Owen, S. D. & Russell, M. W. Neisseria gonorrhoeae selectively suppresses the development of Th1 and Th2 cells, and enhances Th17 cell responses, through TGF-beta-dependent mechanisms. Mucosal Immunol. 5, 320\u2013331 (2012).","journal-title":"Mucosal Immunol."},{"key":"1417_CR45","doi-asserted-by":"publisher","first-page":"126709","DOI":"10.1016\/j.vaccine.2025.126709","volume":"48","author":"EA Islam","year":"2025","unstructured":"Islam, E. A. et al. Adjuvant-dependent impacts on vaccine-induced humoral responses and protection in preclinical models of nasal and genital colonization by pathogenic Neisseria. Vaccine 48, 126709 (2025).","journal-title":"Vaccine"},{"key":"1417_CR46","first-page":"109","volume":"445","author":"A Waltmann","year":"2024","unstructured":"Waltmann, A. et al. Experimental Urethral Infection with Neisseria gonorrhoeae. Curr. Top. Microbiol Immunol. 445, 109\u2013125 (2024).","journal-title":"Curr. Top. Microbiol Immunol."},{"key":"1417_CR47","doi-asserted-by":"publisher","first-page":"975676","DOI":"10.3389\/fimmu.2022.975676","volume":"13","author":"J Shaughnessy","year":"2022","unstructured":"Shaughnessy, J. et al. An optimized Factor H-Fc fusion protein against multidrug-resistant Neisseria gonorrhoeae. Front Immunol. 13, 975676 (2022).","journal-title":"Front Immunol."},{"key":"1417_CR48","doi-asserted-by":"publisher","unstructured":"Bettoni, S. et al. C4BP-IgM protein as a therapeutic approach to treat Neisseria gonorrhoeae infections. JCI Insight 4 https:\/\/doi.org\/10.1172\/jci.insight.131886 (2019).","DOI":"10.1172\/jci.insight.131886"},{"key":"1417_CR49","doi-asserted-by":"publisher","first-page":"S152","DOI":"10.1093\/infdis\/jiab211","volume":"224","author":"KL Connolly","year":"2021","unstructured":"Connolly, K. L. et al. Preclinical Testing of Vaccines and Therapeutics for Gonorrhea in Female Mouse Models of Lower and Upper Reproductive Tract Infection. J. Infect. Dis. 224, S152\u2013S160 (2021).","journal-title":"J. Infect. Dis."},{"key":"1417_CR50","doi-asserted-by":"publisher","unstructured":"Islam, E. A. et al. Specific Binding to Differentially Expressed Human Carcinoembryonic Antigen-Related Cell Adhesion Molecules Determines the Outcome of Neisseria gonorrhoeae Infections along the Female Reproductive Tract. Infect. Immun. 86 https:\/\/doi.org\/10.1128\/IAI.00092-18 (2018).","DOI":"10.1128\/IAI.00092-18"},{"key":"1417_CR51","unstructured":"Connolly, K, M. A. et al. The cross-protective efficacy of the serogroup B meningococcal 4CMenB vaccine against experimental gonococcal infection is less pronounced in Chlamydia-infected mice. 22nd International Pathogenic Neisseria Conference, Cape Town, South Africa, 2022."},{"key":"1417_CR52","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1093\/infdis\/jiae383","volume":"231","author":"WE Abara","year":"2025","unstructured":"Abara, W. E., Kirkcaldy, R. D., Bernstein, K. T., Galloway, E. & Learner, E. R. Effectiveness of MenB-4C Vaccine Against Gonorrhea: A Systematic Review and Meta-analysis. J. Infect. Dis. 231, 61\u201370 (2025).","journal-title":"J. Infect. Dis."},{"key":"1417_CR53","doi-asserted-by":"publisher","first-page":"1274","DOI":"10.1128\/jb.85.6.1274-1279.1963","volume":"85","author":"DS Kellogg Jr","year":"1963","unstructured":"Kellogg, D. S. Jr, Peacock, W. L. Jr, Deacon, W. E., Brown, L. & Pirkle, D. I. Neisseria Gonorrhoeae. I. Virulence Genetically Linked to Clonal Variation. J. Bacteriol. 85, 1274\u20131279 (1963).","journal-title":"J. Bacteriol."},{"key":"1417_CR54","doi-asserted-by":"publisher","first-page":"596","DOI":"10.1128\/jb.96.3.596-605.1968","volume":"96","author":"DS Kellogg Jr","year":"1968","unstructured":"Kellogg, D. S. Jr, Cohen, I. R., Norins, L. C., Schroeter, A. L. & Reising, G. Neisseria gonorrhoeae. II. Colonial variation and pathogenicity during 35 months in vitro. J. Bacteriol. 96, 596\u2013605 (1968).","journal-title":"J. Bacteriol."},{"key":"1417_CR55","doi-asserted-by":"publisher","first-page":"2121","DOI":"10.1084\/jem.168.6.2121","volume":"168","author":"J Swanson","year":"1988","unstructured":"Swanson, J., Barrera, O., Sola, J. & Boslego, J. Expression of outer membrane protein II by gonococci in experimental gonorrhea. J. Exp. Med 168, 2121\u20132129 (1988).","journal-title":"J. Exp. Med"},{"key":"1417_CR56","doi-asserted-by":"publisher","first-page":"532","DOI":"10.1093\/infdis\/169.3.532","volume":"169","author":"MS Cohen","year":"1994","unstructured":"Cohen, M. S. et al. Human experimentation with Neisseria gonorrhoeae: rationale, methods, and implications for the biology of infection and vaccine development. J. Infect. Dis. 169, 532\u2013537 (1994).","journal-title":"J. Infect. Dis."},{"key":"1417_CR57","doi-asserted-by":"publisher","first-page":"123","DOI":"10.3389\/fmicb.2011.00123","volume":"2","author":"MM Hobbs","year":"2011","unstructured":"Hobbs, M. M. et al. Experimental Gonococcal Infection in Male Volunteers: Cumulative Experience with Neisseria gonorrhoeae Strains FA1090 and MS11mkC. Front Microbiol 2, 123 (2011).","journal-title":"Front Microbiol"},{"key":"1417_CR58","doi-asserted-by":"publisher","first-page":"101105","DOI":"10.1016\/j.lanmic.2025.101105","volume":"6","author":"E Williams","year":"2025","unstructured":"Williams, E. et al. Selecting candidate Neisseria gonorrhoeae strains for oropharyngeal gonorrhoea human challenge: a genomics-based analysis of clinical isolates. Lancet Microbe 6, 101105 (2025).","journal-title":"Lancet Microbe"},{"key":"1417_CR59","doi-asserted-by":"publisher","first-page":"636","DOI":"10.12688\/wellcomeopenres.25103.1","volume":"10","author":"E Williams","year":"2025","unstructured":"Williams, E. et al. An oropharyngeal gonorrhoea controlled human infection model: a provisional protocol using a novel Neisseria gonorrhoeae challenge strain. Wellcome Open Res 10, 636 (2025).","journal-title":"Wellcome Open Res"},{"key":"1417_CR60","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1128\/jb.163.2.430-438.1985","volume":"163","author":"C Korch","year":"1985","unstructured":"Korch, C., Hagblom, P., Ohman, H., Goransson, M. & Normark, S. Cryptic plasmid of Neisseria gonorrhoeae: complete nucleotide sequence and genetic organization. J. Bacteriol. 163, 430\u2013438 (1985).","journal-title":"J. Bacteriol."},{"key":"1417_CR61","doi-asserted-by":"publisher","first-page":"630","DOI":"10.1038\/266630a0","volume":"266","author":"M Roberts","year":"1977","unstructured":"Roberts, M. & Falkow, S. Conjugal transfer of R plasmids in Neisseria gonorrhoeae. Nature 266, 630\u2013631 (1977).","journal-title":"Nature"},{"key":"1417_CR62","doi-asserted-by":"publisher","first-page":"e1010743","DOI":"10.1371\/journal.pgen.1010743","volume":"19","author":"WX Yee","year":"2023","unstructured":"Yee, W. X. et al. Evolution, persistence, and host adaption of a gonococcal AMR plasmid that emerged in the pre-antibiotic era. PLoS Genet. 19, e1010743 (2023).","journal-title":"PLoS Genet."},{"key":"1417_CR63","doi-asserted-by":"publisher","first-page":"656","DOI":"10.1016\/S0140-6736(76)92466-1","volume":"2","author":"I Phillips","year":"1976","unstructured":"Phillips, I. Beta-lactamase-producing, penicillin-resistant gonococcus. Lancet 2, 656\u2013657 (1976).","journal-title":"Lancet"},{"key":"1417_CR64","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1016\/S0140-6736(76)92467-3","volume":"2","author":"WA Ashford","year":"1976","unstructured":"Ashford, W. A., Golash, R. G. & Hemming, V. G. Penicillinase-producing Neisseria gonorrhoeae. Lancet 2, 657\u2013658 (1976).","journal-title":"Lancet"},{"key":"1417_CR65","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1128\/CMR.00010-14","volume":"27","author":"M Unemo","year":"2014","unstructured":"Unemo, M. & Shafer, W. M. Antimicrobial resistance in Neisseria gonorrhoeae in the 21st century: past, evolution, and future. Clin. Microbiol Rev. 27, 587\u2013613 (2014).","journal-title":"Clin. Microbiol Rev."},{"key":"1417_CR66","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1099\/00221287-111-1-223","volume":"111","author":"R Laufs","year":"1979","unstructured":"Laufs, R., Kaulfers, P. M., Jahn, G. & Teschner, U. Molecular characterization of a small Haemophilus influenzae plasmid specifying beta-lactamase and its relationship to R factors from Neisseria gonorrhoeae. J. Gen. Microbiol 111, 223\u2013231 (1979).","journal-title":"J. Gen. Microbiol"},{"key":"1417_CR67","doi-asserted-by":"publisher","first-page":"e0044123","DOI":"10.1128\/msphere.00441-23","volume":"8","author":"WX Yee","year":"2023","unstructured":"Yee, W. X., Elsener, T., Cehovin, A., Maiden, M. C. J. & Tang, C. M. Evolution and exchange of plasmids in pathogenic Neisseria. mSphere 8, e0044123 (2023).","journal-title":"mSphere"},{"key":"1417_CR68","doi-asserted-by":"publisher","first-page":"e1013151","DOI":"10.1371\/journal.ppat.1013151","volume":"21","author":"TA Elsener","year":"2025","unstructured":"Elsener, T. A. et al. Origin, evolution, and success of pbla, the gonococcal beta-lactamase plasmid, and implications for public health. PLoS Pathog. 21, e1013151 (2025).","journal-title":"PLoS Pathog."},{"key":"1417_CR69","doi-asserted-by":"publisher","first-page":"1826","DOI":"10.1093\/infdis\/jiaa003","volume":"222","author":"A Cehovin","year":"2020","unstructured":"Cehovin, A., Jolley, K. A., Maiden, M. C. J., Harrison, O. B. & Tang, C. M. Association of Neisseria gonorrhoeae Plasmids With Distinct Lineages and The Economic Status of Their Country of Origin. J. Infect. Dis. 222, 1826\u20131836 (2020).","journal-title":"J. Infect. Dis."},{"key":"1417_CR70","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1016\/S1473-3099(17)30725-9","volume":"18","author":"JM Molina","year":"2018","unstructured":"Molina, J. M. et al. Post-exposure prophylaxis with doxycycline to prevent sexually transmitted infections in men who have sex with men: an open-label randomised substudy of the ANRS IPERGAY trial. Lancet Infect. Dis. 18, 308\u2013317 (2018).","journal-title":"Lancet Infect. Dis."},{"key":"1417_CR71","doi-asserted-by":"publisher","first-page":"1296","DOI":"10.1056\/NEJMoa2211934","volume":"388","author":"AF Luetkemeyer","year":"2023","unstructured":"Luetkemeyer, A. F. et al. Postexposure Doxycycline to Prevent Bacterial Sexually Transmitted Infections. N. Engl. J. Med 388, 1296\u20131306 (2023).","journal-title":"N. Engl. J. Med"},{"key":"1417_CR72","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1093\/infdis\/jiy240","volume":"218","author":"A Cehovin","year":"2018","unstructured":"Cehovin, A. et al. Identification of Novel Neisseria gonorrhoeae Lineages Harboring Resistance Plasmids in Coastal Kenya. J. Infect. Dis. 218, 801\u2013808 (2018).","journal-title":"J. Infect. Dis."},{"key":"1417_CR73","doi-asserted-by":"publisher","first-page":"2331","DOI":"10.1056\/NEJMoa2304007","volume":"389","author":"J Stewart","year":"2023","unstructured":"Stewart, J. et al. Doxycycline Prophylaxis to Prevent Sexually Transmitted Infections in Women. N. Engl. J. Med 389, 2331\u20132340 (2023).","journal-title":"N. Engl. J. Med"},{"key":"1417_CR74","doi-asserted-by":"publisher","unstructured":"Elsener, T. A. et al. There are three major Neisseria gonorrhoeae beta-lactamase plasmid variants which are associated with specific lineages and carry distinct TEM alleles. Microb. Genom. 9 https:\/\/doi.org\/10.1099\/mgen.0.001057 (2023).","DOI":"10.1099\/mgen.0.001057"},{"key":"1417_CR75","doi-asserted-by":"publisher","DOI":"10.1080\/22221751.2024.2440489","volume":"14","author":"XL Qin","year":"2025","unstructured":"Qin, X. L. et al. Emerging epidemic of the Africa-type plasmid in penicillinase-producing Neisseria gonorrhoeae in Guangdong, China, 2013-2022. Emerg. Microbes Infect. 14, 2440489 (2025).","journal-title":"Emerg. Microbes Infect."},{"key":"1417_CR76","doi-asserted-by":"publisher","first-page":"5472","DOI":"10.1128\/JB.183.19.5472-5481.2001","volume":"183","author":"F Pagotto","year":"2001","unstructured":"Pagotto, F. & Dillon, J. A. Multiple origins and replication proteins influence biological properties of beta-lactamase-producing plasmids from Neisseria gonorrhoeae. J. Bacteriol. 183, 5472\u20135481 (2001).","journal-title":"J. Bacteriol."},{"key":"1417_CR77","doi-asserted-by":"publisher","first-page":"1188","DOI":"10.1093\/cid\/ciaf089","volume":"80","author":"OO Soge","year":"2025","unstructured":"Soge, O. O. et al. Potential Impact of Doxycycline Post-Exposure Prophylaxis on Tetracycline Resistance in Neisseria gonorrhoeae and Colonization With Tetracycline-Resistant Staphylococcus aureus and Group A Streptococcus. Clin. Infect. Dis. 80, 1188\u20131196 (2025).","journal-title":"Clin. Infect. Dis."},{"key":"1417_CR78","unstructured":"World Health Organization. Defeating meningitis by 2030: a global road map. (World Health Organization Geneva, 2021)."}],"container-title":["npj Vaccines"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41541-026-01417-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41541-026-01417-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41541-026-01417-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T01:02:06Z","timestamp":1777424526000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41541-026-01417-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,13]]},"references-count":78,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1417"],"URL":"https:\/\/doi.org\/10.1038\/s41541-026-01417-9","relation":{},"ISSN":["2059-0105"],"issn-type":[{"value":"2059-0105","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,13]]},"assertion":[{"value":"7 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"91"}}